News | November 12, 2009

CMS to Cover FDG-PET for Initial Staging of Cervical Cancer

November 12, 2009 - Centers for Medicare & Medicaid Services' (CMS) will expand coverage of FDG-PET for the initial staging of cervical cancer without previously imposed restrictions.

Under the decision, CMS will cover one FDG-PET scan for the staging of cervical cancer. In these cases, physicians can determine the precise location of the tumor and identify the extent to which the tumor has grown. Physicians can then use this information to determine the optimal initial treatment strategy for each individual patient. Additionally, this can help physicians determine whether or not the patient would benefit from further diagnostic tests or therapeutic procedures. Through expanded coverage, physicians can provide patients with an individualized course of therapy—meaning the right treatment at the right time.

The Society for Nuclear Medicine (SNM) applauds this decision. "CMS' decision to expand coverage of FDG-PET for the initial treatment strategy evaluation of cervical cancer is important for patient care," said Michael M. Graham, Ph.D., M.D., president of SNM. "Over the years, the body of scientific evidence has proven the value of molecular imaging scans for diagnosing, staging, restaging and monitoring treatment for many cancers."

SNM and other medical societies encouraged CMS to end the prospective data collection requirements for FDG PET for the initial staging of some patients with cervical cancer. Previously, patients needing PET for initial staging of cervical cancer had to have this performed under the CMS coverage with evidence development policy, if the patient had not first had CT or MRI performed or if other imaging was done but showed evidence of metastatic disease outside of the pelvis. Based on the strong body of evidence, CMS concluded that FDG PET can provide physicians with important information for how to treat patients with cervical cancer without the need for these restrictions.

The recent decision from CMS derives in part from data collected by the National Oncologic PET Registry (NOPR)—a comprehensive study to assess the value of FDG PET for the initial diagnosis, staging and treatment of many common types of cancer. In April 2009, CMS made a decision to expand coverage of FDG PET for breast, cervical, colorectal, esophageal, head and neck, lymphoma, melanoma, non-small cell lung and thyroid cancers.

NOPR is sponsored by the Academy of Molecular Imaging (AMI) and managed by the American College of Radiology (ACR) and ACR Imaging Network (ACRIN). The registry received input from—and is endorsed by—ACR, the American Society for Clinical Oncology (ASCO) and SNM. The NOPR Working Group is chaired by Bruce Hillner, M.D., of Virginia Commonwealth University and co-chaired by Barry Siegel, M.D., Washington University; R. Edward Coleman, M.D., Duke University; and Anthony Shields, M.D., Wayne State University.

For more information: www.snm.org

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init